Form 4: Cytokinetics Director Nancy Wysenski Acquires Shares Through Stock Retainer Program
SEC Form 4 Filing
Director Nancy Wysenski acquired 162 shares of Cytokinetics Inc. common stock through the Director Stock in lieu of Cash Retainer Program.
Summary
- On April 15, 2025, Nancy Wysenski, a director of Cytokinetics Inc., acquired 162 shares of common stock.
- The acquisition was made through the Director Stock in lieu of Cash Retainer Program.
- The price per share was $38.56.
- Following the transaction, Ms. Wysenski beneficially owns 23,277 shares of Cytokinetics Inc. common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a routine transaction related to director compensation.
Positives
- The acquisition of shares by a director may signal confidence in the company's future prospects.
Industry Context
Directors often receive stock as part of their compensation, aligning their interests with those of shareholders. This is a common practice in publicly traded companies.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 04/15/2025 | Date of transaction: Nancy Wysenski acquired 162 shares of Cytokinetics Inc. common stock. |
| 04/16/2025 | Date of signature on the Form 4 filing. |
Keywords
Cytokinetics, Director, Stock, Acquisition, Beneficial Ownership, Form 4, Wysenski, Retainer Program
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.